Huang Jianhua, Li Cheng, Zhang Wentao, Yang Fuhan, Wang Ruiliang, Zhang Junfeng, Li Wei, Yao Xudong
Department of Urology, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Institute of Urinary Oncology, School of Medicine, Tongji University, Shanghai, China.
Ann Transl Med. 2021 Sep;9(18):1439. doi: 10.21037/atm-21-4102.
BACKGROUND: Sulfatase 2 (SULF2) is a member of the sulfatase family, and its expression and clinical significance in bladder cancer (BCa) are not currently known. In this study, we attempted to evaluate SULF2 expression in BCa patients who underwent radical cystectomy (RC) and the relationship between SULF2 expression and clinical-pathological characteristics. METHODS: Data on SULF2 expression in BCa tissues was obtained from the Oncomine database and the Gene Expression Omnibus (GEO). The expression of SULF2 and vascular endothelial growth factor-D (VEGF-D) in BCa was evaluated by immunohistochemistry (IHC) in tissues from 203 patients who had undergone RC. We also explored the value of the measurement of SULF2 and VEGF-D expression for diagnosis and prognosis in BCa patients with lymphatic metastasis. RESULTS: We found an increase in SULF2 messenger RNA (mRNA) levels and gene amplification in BCa tissues from the Oncomine database. High expression of SULF2 was detected in 91/203 (44.8%) of BCa patients. Among these patients, 27 of 42 (64.3%) with lymphatic metastasis showed high SULF2 expression. Univariate analysis showed that tumor size, pathological stage, lymphatic metastasis, vascular infiltration, perineural infiltration, hydronephrosis, and VEGF-D and SULF2 expression were related to prognosis in BCa patients, and multivariable Cox regression analysis showed that SULF2 expression was an independent prognostic indicator. Receiver operating characteristic (ROC) analysis revealed that SULF2 expression resulted in an increased area under the curve (AUC) of 0.707, with a sensitivity of 71.4% and a specificity of 61.5%. CONCLUSIONS: The upregulation of SULF2 is associated with poor prognosis in high-grade BCa patients. It might be a novel diagnostic marker for BCa patients with lymphatic metastasis.
背景：硫酸酯酶2（SULF2）是硫酸酯酶家族的成员，其在膀胱癌（BCa）中的表达及临床意义目前尚不清楚。在本研究中，我们试图评估接受根治性膀胱切除术（RC）的BCa患者中SULF2的表达情况以及SULF2表达与临床病理特征之间的关系。 方法：从Oncomine数据库和基因表达综合数据库（GEO）获取BCa组织中SULF2表达的数据。通过免疫组织化学（IHC）评估203例接受RC患者组织中SULF2和血管内皮生长因子-D（VEGF-D）的表达。我们还探讨了SULF2和VEGF-D表达检测对有淋巴转移的BCa患者诊断和预后的价值。 结果：我们发现Oncomine数据库中BCa组织中SULF2信使核糖核酸（mRNA）水平升高且基因扩增。在203例BCa患者中有91例（44.8%）检测到SULF2高表达。在这些患者中，42例有淋巴转移的患者中有27例（64.3%）显示SULF2高表达。单因素分析显示肿瘤大小、病理分期、淋巴转移、血管浸润、神经周围浸润、肾积水以及VEGF-D和SULF2表达与BCa患者的预后相关，多变量Cox回归分析显示SULF2表达是一个独立的预后指标。受试者工作特征（ROC）分析显示SULF2表达使曲线下面积（AUC）增加到0.707，敏感性为71.4%，特异性为61.5%。 结论：SULF2的上调与高级别BCa患者的不良预后相关。它可能是有淋巴转移的BCa患者的一种新型诊断标志物。
Cancers (Basel). 2022-12-26
J Clin Invest. 2020-1-2
Zhonghua Zhong Liu Za Zhi. 2018-9-23
Minerva Urol Nefrol. 2016-4
Virchows Arch. 2014-4-4
Eur Urol. 2013-4-29
Zotero 插件
